P.A.W. Capital Corp Abb Vie Inc. Transaction History

P.A.W. Capital Corp

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 13, 2022	SELL	$137.62 - $174.96 $68,810 - $87,480	-500 Reduced 8.33%	5,500 $842,000
Q1 2022 Apr 21, 2022	SELL	$131.98 - $163.75 $131,980 - $163,750	-1,000 Reduced 14.29%	6,000 $973,000
Q2 2020 Jul 27, 2020	SELL	$73.37 - $98.18 $73,370 - $98,180	-1,000 Reduced 12.5%	7,000 $687,000
Q2 2019 Jul 31, 2019	BUY	$65.7 - $83.98 $32,850 - $41,990	500 Added 6.67%	8,000 $582,000
Q1 2019 Apr 17, 2019	BUY	$77.14 - $90.79 $77,140 - $90,790	1,000 Added 15.38%	7,500 $604,000
Q2 2018 Jul 25, 2018	BUY	$89.78 - $106.23 $44,890 - $53,115	500 Added 8.33%	6,500 $602,000
Q1 2018 Apr 26, 2018	SELL	$92.01 - $123.21 $138,015 - $184,815	-1,500 Reduced 20.0%	6,000 $568,000
Q4 2017 Jan 31, 2018	SELL	$89.56 - $98.21 $134,340 - $147,315	-1,500 Reduced 16.67%	7,500 $725,000
Q3 2017 Oct 23, 2017	BUY	$69.85 - $89.22 $628,650 - $802,980	9,000	9,000 $800,000

4,095

1.28B

16.7M

15M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $357B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of P.A.W. Capital Corp, based on Form 13F filings with the SEC.

Stay updated on P.A.W. Capital Corp with notifications on news.